# A Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibitor (Itraconazole) and Inducer (Rifampin) on the Drug Levels of Golcadomide (BMS-986369) in Healthy Participants

> **NCT06363630** · PHASE1 · COMPLETED · sponsor: **Celgene** · enrollment: 35 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Itraconazole
- **DRUG:** Rifampin
- **DRUG:** Golcadomide

## Key facts

- **NCT ID:** NCT06363630
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-04-23
- **Primary completion:** 2024-08-29
- **Final completion:** 2024-08-29
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2024-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06363630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06363630, "A Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibitor (Itraconazole) and Inducer (Rifampin) on the Drug Levels of Golcadomide (BMS-986369) in Healthy Participants". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT06363630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*